Search
XtalPi Announces Letter of Intent for Multi-Billion-Dollar Drug Pipeline Collaboration with DoveTree, a Novel Drug Development Company
3 day ago /
Read about 0 minute
Author：小编
XtalPi has entered into a letter of intent with DoveTree LLC, a company founded by Harvard University Professor Gregory Verdine, to harness its cutting-edge AI+robotics platform for the development and discovery of small molecule and antibody drug candidates. These candidates will target areas identified by DoveTree in oncology, autoimmune diseases, and neurological disorders. Upon signing the agreement, XtalPi will receive phased upfront payments, with the potential to earn multi-billion-dollar milestone payments and royalties. In return, DoveTree will secure exclusive global rights for the development and commercialization of these innovative therapeutic products.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
